TRAF3 Polyclonal Antibody, Cy7 Conjugated

Applications

  • WB
  • FCM
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Human
  • Mouse

Predicted Reactivity

  • Rat
Overview
Catalog # bs-1185R-Cy7
Product Name TRAF3 Polyclonal Antibody, Cy7 Conjugated
Applications WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Human, Mouse
Predicted Reactivity Rat
Specifications
Conjugation Cy7
Host Rabbit
Source KLH conjugated synthetic peptide derived from human TRAF3
Immunogen Range 101-200/568
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 7187
Swiss Prot Q13114
Subcellular location Cytoplasm
Synonyms CAP1; LAP1; CAP-1; CRAF1; IIAE5; CD40bp; TNF receptor-associated factor 3; CD40 receptor-associated factor 1; CD40-binding protein; LMP1-associated protein 1; TRAF3
Background Regulates pathways leading to the activation of NF-kappa-B and MAP kinases, and plays a central role in the regulation of B-cell survival. Part of signaling pathways leading to the production of cytokines and interferon. Required for normal antibody isotype switching from IgM to IgG. Plays a role T-cell dependent immune responses. Plays a role in the regulation of antiviral responses. Is an essential constituent of several E3 ubiquitin-protein ligase complexes. May have E3 ubiquitin-protein ligase activity and promote 'Lys-63'-linked ubiquitination of target proteins. Inhibits activation of NF-kappa-B in response to LTBR stimulation. Inhibits TRAF2-mediated activation of NF-kappa-B. Down-regulates proteolytic processing of NFKB2, and thereby inhibits non-canonical activation of NF-kappa-B. Promotes ubiquitination and proteasomal degradation of MAP3K14.
Application Dilution
WB 1:300-5000
FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200